Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SPRC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.20
N/A
-0.26
vs -0.20
Q4.20
+100%
NA
vs -0.32
Q2.21
N/A
-0.22
vs -0.26
Q4.21
N/A
-26.40
vs NA
Q2.22
N/A
-46.80
vs -0.22
Q4.22
+152%
13.83
vs -26.40
Q2.23
N/A
-10.18
vs -46.80
Q4.23
N/A
-4.20
vs 13.83
Q2.24
N/A
-1.70
vs -10.18
Q3.24
N/A
1.54
vs NA
Sales Growth
YoY
Current
Estimates
Q2.20
NA
NA vs NA
Q4.20
+10%
550K vs 498K
Q2.21
NA
NA vs NA
Q4.21
+94%
1.1M vs 550K
Q2.22
NA
NA vs NA
Q4.22
+26%
1.3M vs 1.1M
Q2.23
NA
2M vs NA
Q4.23
-33%
907K vs 1.3M
Q2.24
-57%
840K vs 2M
Q3.24
NA
941.3K vs NA
Return on Equity
QoQ
Q4.20
-59%
-0.59
vs 3.8
Q2.21
-35%
-0.35
vs -0.59
Q4.21
-39%
-0.39
vs -0.35
Q2.22
-190%
-1.90
vs -0.39
Q4.22
+49%
0.49
vs -1.90
Q2.23
-70%
-0.70
vs 0.49
Q4.23
-29%
-0.29
vs -0.70
Q2.24
-50%
-0.50
vs -0.29
Institutionnal Ownership
QoQ
Q4.21
1
1
vs NA
NA
Q1.22
3
3
vs 1
200%
Q2.22
4
4
vs 3
33%
Q3.22
2
2
vs 4
-50%
Q4.22
3
3
vs 2
50%
Q1.23
8
8
vs 3
167%
Q2.23
6
6
vs 8
-25%
Quote Panel
Key Metrics
Forecast
781007%2025-Revenue
102%2025-EPS
-198246%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Relative Strength
SPRC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
NASDAQ
Unprofitable
Unprofitable
-0.00 ( -1.11%)
Relative Strenght
2
Volume Buzz
-77%
Earning Acce
Yes
Dist 52w H.
84%